普罗帕酮对川崎病合并心律失常患儿心功能、炎性指标及不良反应的影响分析  

Effects of propafenone on cardiac function, inflammatory indexes and adverse reactions in children with Kawasaki's disease complicated with arrhythmia

作　　者：孙蕊蕊 张益萍 SUN Rui-rui;ZHANG Yi-ping(Department of Pediatrics,The Second Hospital of Weihai of Qingdao University,Weihai 264200,China)

机构地区：[1]青岛大学附属威海市立第二医院儿科,264200 [2]威海市立第三医院,264200

出　　处：《中国现代药物应用》2025年第6期76-79,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨普罗帕酮对川崎病合并心律失常患儿炎性指标、心功能以及不良反应的影响。方法选取川崎病合并心律失常患儿80例,按照不同治疗方法分为研究组和对照组,各40例。对照组使用美托洛尔治疗,研究组使用普罗帕酮治疗。对比两组患儿临床症状消退时间、心功能指标[左室射血分数(LVEF)、心排血指数(CI)、左室舒张末期内径(LVEDD)]、炎性指标[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)、降钙素原(PCT)]、不良反应发生率。结果治疗后,研究组患儿黏膜充血、皮疹、手足肿胀、高热消退时间分别为(2.64±0.77)、(3.83±1.25)、(3.84±1.32)、(1.25±0.35)d,均比对照组的(4.42±1.03)、(6.51±2.12)、(5.91±1.41)、(3.57±1.09)d短(P<0.05)。治疗后,研究组患儿LVEDD(3.06±0.14)cm比对照组的(3.46±0.25)cm小,LVEF(57.38±4.32)%、CI(3.58±0.32)L/(min·m^(2))比对照组的(52.02±3.56)%、(3.11±0.31)L/(min·m^(2))高(P<0.05)。治疗后,研究组患儿IL-6(20.48±2.24)ng/ml、TNF-α(6.01±0.19)pg/ml、PCT(0.45±0.13)ng/ml、hs-CRP(33.35±3.14)mg/L均比对照组的(32.38±3.39)ng/ml、(7.53±0.27)pg/ml、(1.31±0.28)ng/ml、(60.74±3.19)mg/L低(P<0.05)。治疗后,研究组不良反应发生率和对照组对比差异无统计学意义(P>0.05)。结论与美托洛尔相比,川崎病合并心律失常患儿给予普罗帕酮治疗效果更佳,可缩短患儿临床症状消退时间,促进心功能指标及炎性指标改善,且用药后并不会出现严重不良反应,具有较高的安全性。Objective To explore the effects of propafenone on cardiac function, inflammatory indexes and adverse reactions in children with Kawasaki's disease complicated with arrhythmia. Methods 80 children with Kawasaki's disease complicated with arrhythmia were selected and divided into study group and control group according to different treatment methods, with 40 cases in each group. The control group was treated with metoprolol, and the study group was treated with propafenone. Both groups were compared in terms of resolution time of clinical symptoms, cardiac function indexes[ left ventricular ejection fraction (LVEF), cardiac index (CI), left ventricular end-diastolic diameter (LVEDD)], inflammatory indicators[ interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), hypersensitive C-reactive protein (hs-CRP), and procalcitonin (PCT)], incidence of adverse reactions. Results After treatment, the resolution time of mucosal congestion, rash, hand and foot swelling and high fever in the study group were (2.64±0.77), (3.83±1.25), (3.84±1.32) and (1.25±0.35) d, which were shorter than (4.42±1.03), (6.51±2.12), (5.91±1.41) and (3.57±1.09) d in the control group (P<0.05). After treatment, the study group had a smaller LVEDD of (3.06±0.14) cm than (3.46±0.25) cm in the control group;the study group had LVEF of (57.38±4.32) % and CI of (3.58±0.32) L/(min·m^(2)), which were higher than (52.02±3.56) % and (3.11±0.31) L/(min·m^(2)) in the control group (P<0.05). After treatment, the study group had IL-6 of (20.48±2.24) ng/ml, TNF-α of (6.01±0.19) pg/ml, PCT of (0.45±0.13) ng/ml, and hs-CRP of (33.35±3.14) mg/L, which were lower than (32.38±3.39) ng/ml, (7.53±0.27) pg/ml, (1.31±0.28) ng/ml, and (60.74±3.19) mg/L in the control group (P<0.05). After treatment, there was no statistically significant difference in the incidence of adverse reactions between the study group and the control group (P>0.05). Conclusion Compared with metoprolol, propafenone has a better therapeutic effect on patients with Kawasak

关 键 词：普罗帕酮 川崎病 心律失常 心功能 炎性指标 不良反应 

分 类 号：R725.4[医药卫生—儿科]